Metformin's Role in Treating Liver Disease
Author Information
Author(s): Chen Hang, Huang Minshan, Zhang Dan, Wang Hui, Wang Da, Li Mengwei, Wang Xianmei, Zhu Rui, Liu Jianjun, Ma Lanqing
Primary Institution: The First Affiliated Hospital, Yunnan Institute of Digestive Disease, Kunming Medical University, Kunming, China
Hypothesis
This study investigates the role of miR-200a-5p in the AMPK/SERCA2b pathway and how metformin affects metabolic dysfunction-associated steatotic liver disease (MASLD).
Conclusion
Metformin reduces liver fat accumulation and ER stress in MASLD by modulating the AMPK/SERCA2b pathway through miR-200a-5p.
Supporting Evidence
- Metformin treatment reduced liver steatosis and lipid deposition in mice.
- Elevated serum miR-200a-5p was detected in MASLD patients.
- miR-200a-5p levels were elevated in the HFD group but decreased in the HFD + Met group.
Takeaway
Metformin helps people with liver disease by lowering fat in the liver and reducing stress on liver cells.
Methodology
The study used a high-fat diet-induced mouse model and a cell model to assess lipid accumulation and gene expression through various biochemical assays.
Limitations
The study did not validate the miR-200a-5p and AMPK relationship at the animal level.
Participant Demographics
10 healthy volunteers and 10 MASLD patients were included.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website